Dabur Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 2.10 Cr
as on 23-10-2024
- Paid Up Capital ₹ 1.59 M
as on 23-10-2024
- Company Age 39 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit 3.60%
(FY 2023)
- Ebitda 31.71%
(FY 2023)
- Net Worth -11.03%
(FY 2023)
- Total Assets -7.64%
(FY 2023)
About Dabur Pharmaceutical
The Corporate was formerly known as Key Pharmaceuticals Ltd. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.10 Cr and a paid-up capital of Rs 1.59 M, as per Ministry of Corporate Affairs (MCA) records.
Anurag Gupta, Pankaj Bhardwaj, and Akhil Mahajan serve as directors at the Company.
- CIN/LLPIN
U24231DL1985PLC021308
- Company No.
021308
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
25 Jun 1985
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Dabur Pharmaceutical?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anurag Gupta  | Director | 27-Mar-2015 | Current |
| Pankaj Bhardwaj | Director | 25-Jul-2019 | Current |
| Akhil Mahajan | Director | 01-Feb-2024 | Current |
Financial Performance and Corporate Structure Insights of Dabur Pharmaceutical.
Dabur Pharmaceutical Ltd, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a slight improvement in profitability, with a 3.6% increase in profit. The company's net worth observed a substantial decline by a decrease of 11.03%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dabur Pharmaceutical?
In 2023, Dabur Pharmaceutical had a promoter holding of 97.11% and a public holding of 2.89%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Param Investments Private LimitedActive 40 years 23 daysPankaj Bhardwaj and Akhil Mahajan are mutual person
_LIMITED.webp)
Dabur Ayurvedic Specialities LimitedActive 31 years 3 monthsPankaj Bhardwaj and Akhil Mahajan are mutual person
_LIMITED.webp)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Dabur Pharmaceutical?
Unlock and access historical data on people associated with Dabur Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dabur Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dabur Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
